• Explore /
  • Poster
  • / Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).

Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Michael Geissler

Klinikum Esslingen, Department of Internal Medicine, Oncology/Hematology, Gastroenterology, Esslingen, Germany

Michael Geissler , Jorge Riera-Knorrenschild , Uwe Marc Martens , Swantje Held , Jobst Greeve , Axel Florschütz , Thomas Jens Ettrich , Stephan Kanzler , Andrea Tannapfel , Volker Heinemann , Anke C. Reinacher-Schick , Thomas Seufferlein , Swen Wessendorf , Dominik Paul Modest

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01328171

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3511)

DOI

10.1200/JCO.2019.37.15_suppl.3511

Abstract #

3511

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Michael Geissler

First Author: Sara Lonardi

First Author: Veronica Conca

First Author: Takanori Watanabe